EUVIMEDEUVIMED entdecken
Open Access

Risk of Cardiorespiratory Events Following Respiratory Syncytial Virus–Related Hospitalization

Caihua Liang, Jennifer Judy, Negar Aliabadi, Reiko Sato, Erica Chilson, Yun Zhou, Xin Zhao, Bradford D Gessner, Elizabeth Begier

JAMA Network Open · 2026

DOI: 10.1001/jamanetworkopen.2025.56767 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2026. Verfasst von Caihua Liang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vaccines Real-World Evidence (RWE) Epidemiology, Pfizer Inc, New York, New York. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Hospitalization, Cardiovascular Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Respiratory syncytial virus (RSV) may trigger cardiorespiratory events in adults.

Objective

To assess the risk of cardiorespiratory events in the 180 days following RSV-related hospitalization compared with a control period in adults. Design, Setting, and Participants This self-controlled case series study had an observation period from January 1, 2017, through March 31, 2024. Data were obtained from the deidentified Optum Market Clarity Dataset, including RSV-related hospitalization and associated outcomes, which were identified based on diagnosis codes. Adults with 1 or more RSV-related hospitalizations and 1 or more cardiorespiratory events (myocardial infarction [MI], stroke, chronic obstructive pulmonary disease [COPD] exacerbation, congestive heart failure [CHF] exacerbation, and arrhythmia) were included. Exposure RSV-related hospitalization. Main Outcomes and Measures A conditional Poisson regression model was fitted to compare the incidence of cardiorespiratory events during the risk period (ie, ≤180 days after RSV-related hospital index date) and control periods (ie, >21 days before or >180 days after the index date). Incidence rate ratios (IRRs) and 95% CIs were estimated and adjusted for time-varying covariates.

Results

A total of 11 887 patients (mean [SD] age, 69.4 [15.5] years; 7303 females [61.4%]) with RSV-related hospitalization were included. An increased risk was associated with each cardiorespiratory event during the first 14 days following RSV-related hospitalization, with the highest IRR estimates observed in the initial 7 days. For MI, the IRRs were 8.7 (95% CI, 6.7-11.2) during days 1 to 7, decreasing to 5.2 (95% CI, 3.7-7.2) during days 8 to 14 and 2.6 (95% CI, 1.6-4.3) during days 15 to 21. For stroke, the IRRs were 7.4 (95% CI, 5.5-10.1), 5.9 (95% CI, 4.2-8.3), and 3.7 (95% CI, 2.3-5.9) during the first 3 weeks with a similar pattern for CHF exacerbation (12.5 [95% CI, 10.5-14.8], 4.1 [95% CI, 3.1-5.5], and 2.4 [95% CI, 1.6-3.6], respectively). For COPD exacerbation and arrhythmia, the IRRs decreased during the first 3 weeks from 23.1 (95% CI, 20.2-26.5) through day 7 to 1.3 (95% CI, 0.8-2.4) during days 15 to 21 and from 16.5 (95% CI, 14.5-18.7) to 1.6 (95% CI, 1.1-2.5), respectively. Conclusions and Relevance This study demonstrated that RSV, similar to influenza and SARS-CoV-2, was associated with an increased risk of cardiorespiratory events 2 weeks following RSV-related hospitalization, and some conditions had significant risk elevations up to 180 days after admission. The findings reinforce the need to increase RSV immunization in adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsHospitalizationCardiovascular DiseasesHumansFemaleAgedMaleMiddle AgedMyocardial InfarctionHeart FailureIncidencePulmonary Disease, Chronic ObstructiveRisk FactorsArrhythmias, CardiacStroke

Autor:innen und Institutionen

  • Vaccines Real-World Evidence (RWE) Epidemiology, Pfizer Inc, New York, New York.
  • US Medical Affairs, Vaccines, Pfizer Inc, New York, New York.
  • Health Technology Assessment (HTA) Value and Evidence, Pfizer Inc, Collegeville, Pennsylvania.
  • RWE Health Economics and Outcomes Research (HEOR) Scientific Solutions Division, Genesis Research Group, Hoboken, New Jersey.
  • Global Medical Strategy, Pfizer Inc, Dublin, Ireland.

Zitieren

APA

Liang, C., Judy, J., Aliabadi, N., Sato, R., Chilson, E., Zhou, Y., Zhao, X., Gessner, B. D., & Begier, E. (2026). Risk of Cardiorespiratory Events Following Respiratory Syncytial Virus–Related Hospitalization. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.56767

Vancouver

Liang C, Judy J, Aliabadi N, Sato R, Chilson E, Zhou Y, et al. Risk of Cardiorespiratory Events Following Respiratory Syncytial Virus–Related Hospitalization. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2025.56767

BibTeX
@article{Liang2026,
  author = {Liang, Caihua and Judy, Jennifer and Aliabadi, Negar and Sato, Reiko and Chilson, Erica and Zhou, Yun and Zhao, Xin and Gessner, Bradford D and Begier, Elizabeth},
  title = {Risk of Cardiorespiratory Events Following Respiratory Syncytial Virus–Related Hospitalization},
  journal = {JAMA Network Open},
  year = {2026},
  doi = {10.1001/jamanetworkopen.2025.56767}
}
Kostenlos starten →